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Specific antibodies against rapl A and rapl B small GTP-binding proteins were generated by 
immunization of rabbits with peptides derived from the C-terminus of the processed proteins. 
Immunoblot analysis of membranes from several mammalian cell lines and human thrombocytes 
with affinity-purified antibodies against raplA or raplB demonstrated the presence of multiple 
immunoreactive proteins in the 22 - 23 kDa range, although at strongly varying levels. Whereas both 
proteins were present in substantial amounts in membranes from myelocytic HL-60, K-562 and 
HEL cells, they were hardly detectable in membranes from lymphoma U-937 and S49.1 cyc- cells. 
Membranes from human thrombocytes and 3T3-Swiss Albino fibroblasts showed strong rapl B 
immunoreactivity, whereas raplA protein was present in much lower amounts. In the cytosol of HL- 
60 cells, only small amounts of raplA and raplB proteins were detected, unless the cells were treated 
with lovastatin, an inhibitor of hydroxymethylglutaryl-coenzyme A reductase, suggesting that both 
proteins are isoprenylated. By comparison with recombinant proteins, the ratio of rapl A/ras proteins 
in membranes from HL-60 cells was estimated to be about 4: 1. An antiserum directed against the C- 
terminus of rap2 reacted strongly with recombinant rap2, but not with membranes from tested 
mammalian cells. In conclusion, rapl A and rapl B proteins are distributed differentially among 
membranes from various mammalian cell types and are isoprenylated in HL-60 cells. 
The rap proteins belong to the rapidly growing family of 
small GTP-binding proteins [I -31. Up till now, amino acid 
sequences for four types of rap proteins have been deduced 
from cloned cDNA, namely raplA [4-71, raplB [8], rap2 [4] 
and rap2B [9]. Except for their C-terminal sequences, the rap 
proteins are highly similar to each other and share the effector 
domain with ras proteins [l -31. 
The C-terminus of ras proteins is essential for attaching 
the proteins to the plasma membrane, largely by modifications 
to the last four amino acids, the so-called CAAX motif. These 
modifications include attachment of a C15 (farnesyl) isopre- 
noid to the cysteine of the CAAX motif, removal of the final 
three amino acids and methylation of the newly exposed Ca 
group [lo]. More recently, it was shown that raplA protein 
expressed in insect cells [ll] and raplB protein purified from 
human platelets [12] are modified by a C20 (geranylgeranyl) 
isoprenoid. 
Little is known about the function of rap proteins in mam- 
malian cells. Interest has focussed on the raplA (Krev-I) 
protein, whose cDNA was cloned first using the feature of its 
homology to ras proteins [4] and more recently by its ability 
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to suppress the transformed phenotype of fibroblasts induced 
by oncogenic ras protein [6]. Overexpression of raplA in ras- 
transformed fibroblasts restores the platelet derived growth 
factor-mediated activation of phospholipase C and the induc- 
tion of growth-related genes [I 31. I t  has been shown that raplA 
binds to ras GTPase-activating protein (GAP), although the 
GTPase activity of raplA is not stimulated [14- 171. Further- 
more, the GTP-bound form of raplA is an effective competi- 
tive inhibitor of the GAP-mediated GTPase activity of ras 
proteins [14, 151. This suggests that raplA competes with ras 
for GAP in intact cells and blocks downstream signalling. 
Since GAP proteins have been identified which specifically 
stimulate the GTPase activity of rapl proteins [I& 191, it is 
also possible that raplA controls a signalling pathway antag- 
onistic to ras. More recently, an antagonistic action of the 
rapl B protein on ras-induced germinal-vesicle breakdown in 
Xenopus oocytes was reported [20]. 
In neutrophils, rapl is associated with a molecular com- 
plex at the plasma membrane which is responsible for 
superoxide generation [21, 221. More recently, it was shown 
that the activation of NADPH oxidase from macrophages 
involves the small GTP-binding protein, racl [23]. Using an 
antiserum recognizing both raplA and raplB, Kim et al. 
[24] found that rapl proteins are present in the particulate 
fractions, but not in the cytosol prepared from cerebrum. 
Beranger et al. [25] utilized an antiserum directed against 
both raplA and raplB to demonstrate the association of rapl 
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proteins with the Golgi complex of mammalian cells. There is 
also evidence that raplB associates with the platelet cyto- 
skeleton [26]. 
In this paper, we report on the production of specific 
antibodies directed against the C-terminus of rap1 A, raplB 
or rap 2 and their use in immunoblot analysis of these proteins 
in membranes from various mammalian cell lines including 
HL-60 cells and human thrombocytes. Additionally, inhi- 
bition of isoprenoid biosynthesis by lovastatin was used to 
show that raplA and raplB proteins are isoprenylated and 
thereby attached to membranes in HL-60 cells. 
MATERIALS AND METHODS 
Materials 
Materials were obtained from the following sources: nitro- 
cellulose membranes (BA83,0.2 pm) from Schleicher & Schiill 
(Dassel, FRG), [LX-~'P]GTP (3000 Ci/mmol) from New 
England Nuclear (Dreieich, FRG), Hyperfilm-MP from 
Amersham Buchler (Braunschweig, FRG), Tween 20 from 
BioRad (Munich, FRG). Materials for gel electrophoresis 
were purchased from BioRad (Munich, FRG). All other 
chemicals were of reagent grade and obtained from Merck 
(Darmstadt, FRG). 
Lovastatin was generously supplied by Dr A. Alberts 
(Merck, Sharp and Dohme, Rahway, NJ, USA). 
Preparation of antibodies specific for raplA and raplB proteins 
Synthetic peptides derived from the C-terminal region of 
raplA, raplB and rap2 proteins were used to generate 
polyclonal antibodies in rabbits. Peptides were coupled via 
the C-terminal cysteine residue to keyhole limpet hemocyanin 
as described [27]. Briefly, 800 pg dissolved peptide and 500 pg 
activated keyhole limpet hemocyanin were stirred for 3 h at 
room temperature. The reaction mixture was applied to a PD- 
10 column (Pharmacia, Freiburg, FRG). Fractions with high 
protein content were collected and rechromatographed. As- 
suming a coupling efficiency of loo%, rabbits were immunized 
with 170 pg coupled peptide in complete Freund's adjuvant 
and boostered one month later with 100 pg coupled peptide 
in incomplete Freund's adjuvant. Rabbits were bled in inter- 
vals of two weeks after the booster. 
RaplA antiserum 21 3, raplB antiserum 218 and rap2 anti- 
serum 221 were subjected to affinity chromatography, using 
immobilized peptides coupled to Affi-Gel (BioRad, Munich, 
FRG). 
Expression of recombinant rap proteins in Escherichia coli 
Recombinant raplA [15] and rap2 proteins [28] were pro- 
duced in E. coli using the ptaq 32 vector. Colonies were grown 
overnight at 37°C in 50 ml of Luria-Bertani medium contain- 
ing 50 pg/ml of both ampicillin and kanamycin. A 10 ml 
sample of this culture was then used to inoculate 1000 ml 
medium. The culture was allowed to grow at 37°C to an A600 
of about 0.5. Isopropylthio-P-D-galactoside was added to a 
final concentration of 0.5 mM and the culture was incubated 
for 3 hat  37 "C. Bacteria were harvested by centrifugation and 
the cell sediment was lysed at room temperature in sample 
buffer according to Laemmli [29]. The lysate was cleared by 
centrifugation and an aliquot of the supernatant was subjected 
to SDSjPAGE and immunoblot analysis. 
Culture of HL-60 cells 
HL-60 cells were grown in suspension culture in RPMI- 
1640 medium supplemented with 10% (by vol.) horse serum, 
1 % (by vol.) non-essential amino acids, 2 mM L-glutamine, 
50 Ujml penicillin and 50 pg/ml streptomycin in a humidified 
atmosphere with 7% C 0 2  at 37°C. 
HL-60 cells, at a density of about 5 x lo5 cells/ml, were 
treated for 72 h with 10 pM lovastatin or its vehicle. 
Lovastatin at this concentration was not cytotoxic to HL-60 
cells, as revealed by trypan blue exclusion and did not effect 
cell growth, as revealed by the analysis of cell growth curves 
(data not shown). Additionally, lovastatin did not induce 
morphological maturation of HL-60 cells or functional differ- 
entiation, as revealed by the analysis of Pappenheim-stained 
smears of cells (J. Oertel, unpublished results) and measure- 
ment of phorbol-myristate-acetate-induced superoxide forma- 
tion (data not shown). 
Preparation of membranes and cytosol from HL-60 cells 
HL-60 and other cultured cells were disrupted by nitrogen 
cavitation and membranes (40000 x g sediment) were pre- 
pared as described [30]. Cytosol(l80000 x g supernatant) was 
isolated by spinning the 40000 x g  supernatant for 1 h at 
180000 x g and 4 "C. Samples were frozen in aliquots in liquid 
nitrogen and stored at - 80°C. Protein concentrations were 
determined by the method of Peterson [31], using bovine serum 
albumin as a standard. 
SDS/polyacrylamide gel electrophoresis 
Before application to the gel, proteins were precipitated 
by acetone, dissolved in sample buffer according to Laemmli 
[29] and heated for 5 min at 95 "C. 50 pg protein/lane, together 
with molecular-mass-marker proteins (Sigma, Deisenhofen, 
FRG) were separated on SDS/polyacrylamide gels prepared 
by the method of Laemmli [29]. The slab gels (1 mm thick) 
consisted of a 5% stacking gel (10mm long) and a 12.5% 
separating gel (50 mm long). 
Immunoblot analysis 
Subsequently to SDS/PAGE, proteins were electrotrans- 
ferred onto nitrocellulose membranes for 2 h at 100 V [32]. 
Proteins on blots were stained with Poinceau S to ascertain 
that comparable amounts of protein were loaded in each lane. 
The nitrocellulose sheets were then reacted with the appropri- 
ate dilution of rabbit antiserum followed by anti-(rabbit- 
IgG) - alkaline-phosphatase conjugate, or mouse monoclonal 
antibody followed by anti-(mouse-IgG) - alkaline-phospha- 
tase conjugate, as specified by the manufacturer's instructions 
(Promega, Madison, WI, USA). Two mouse monoclonal anti- 
bodies were used for this study, Tumark-ras 11 (NEN, 
Dreieich, FRG) [33] and 142-24E05 (Microbiological Associ- 
ates, Bethesda, MD, USA) [34]. The intensity of the bands 
on immunoblots was evaluated using a video densitometer 
(Biotec-Fischer, Reiskirchen, FRG). 
RESULTS 
We selected peptides covering the C-terminal sequences of 
raplA (amino acid residues 168-181), raplB (amino acid 
residues 168 - 181) and rap2 (amino acid residues 164 - 177) 
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Fig. 1. Comparison of C-terminal amino acid sequences of c-Ha-ras and 
rap proteins. C-terminal amino acid sequences of primary proteins 
encoded by human cDNA clones for c-Ha-ras [I], raplA [4], raplB 
[8], rap2 [4], and rap2B [9] are compared. Ras and rap primary proteins 
undergo complex C-terminal processing events, e.g. the last three 
amino acids are proteolytically removed, so that cysteine becomes the 
C-terminal residue. Sequences of synthetic peptides used for gener- 
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Fig. 2. Characterization of affinity-purified antibodies raised against 
rap proteins by immunoblot analysis. 100 ng purified recombinant 
c-Ha-ras protein (lane I), a lysate from E. coli producing raplA (lane 
2). an extract from yeast S.  cerevisiae expressing raplB (lane 3) and 
a lysate from E. coli producing rap2 (lane 4) were subjected to SDS/ 
PAGE and transferred to nitrocellulose. Blots were reacted with affin- 
ity-purified rapl A-antiserum 21 3 (A), raplB-antiserum 218 (B) and 
rap2-AS 221 (C),  rasll mAb (D) and 142-24E05 mAb (E). Values on 
the right indicate the position of molecular-mass-marker proteins. 
(Fig. 1) to generate antibodies in rabbits. The specificity of 
affinity-purified antibodies against raplA (antiserum 21 3), 
raplB (antiserum 218) and rap2 (antiserum 221) was tested 
in immunoblot experiments with recombinant rap proteins. 
Affinity-purified antibodies against rapl A, rapl B and rap2 
exclusively reacted with the corresponding recombinant rap 
proteins and showed no cross-reactivities (Fig. 2). Rapl A- 
antiserum 21 3 recognized two bands of approximately 22 kDa 
and 23 kDa in lysates from E. coli cells producing raplA 
protein (see Fig. 2). RaplB-antiserum 218 exclusively reacted 
with a band of approximately 22 kDa in extracts from yeast 
Saccharomyces cerevisiae producing rapl B protein (Fig. 2). 
Rap2-antiserum 221 showed strong reactivity towards a single 
1 2 3 4 5 6 7 8  kDa 














Fig. 3. Immunoblot analysis of rap and ras proteins in membranes from 
mammalian cell lines and human thrombocytes. 50 pg membrane pro- 
teins from HL-60 cells (lane I), U-937 cells (lane 2), P388D1 cells (lane 
3), K-562 cells (lane 4), HEL cells (lane 5) ,  human thrombocytes (lane 
6), S49.1 cyc- cells (lane 7) and 3T3-Swiss Albino fibroblasts (lane 8) 
were subjected to SDSjPAGE and transferred to nitrocellulose. Blots 
were reacted with 142-24E05 mAb (A), affinity-purified rapl A-anti- 
serum 213 (B), rapl B-antiserum 218 (C), rap2-antiserum 221 (D) and 
rasll mAb (E). Values on the right indicate the position of molecular- 
mass-marker proteins. 
band of approximately 21 kDa in lysates from E.  coli cells 
producing rap2 protein (Fig. 2). Binding of affinity-purified 
rap antibodies to recombinant rap proteins and to membranes 
from HL-60 cells was blocked by prior incubation of anti- 
bodies with the peptides used for immunization (data not 
shown). 
Purified recombinant c-Ha-ras protein [35], which strongly 
reacted with the panreactive monoclonal antibody rasl 1, was 
not recognized by the affinity-purified antibodies against 
raplA, raplB and rap2 proteins (Fig. 2). rasll  monoclonal 
antibody showed only minor cross-reactivity with recombi- 
nant rap proteins (see Fig. 2). 
We also tested monoclonal antibody 142-24E05, which 
was raised against a synthetic peptide consisting of amino acid 
residues 96 - 118 of ras proteins [34] and which cross-reacts 
with rapl proteins [21]. This antibody displayed high reactivity 
against recombinant c-Ha-ras, rapl A and raplB, whereas 
recombinant rap2 was only weakly recognized (Fig. 2). This 
result is in line with a comparison of amino acid sequences 
between ras and rap proteins, showing that the amino acid 
sequence corresponding to c-Ha-ras residues 96 - 11 8 is less 
conserved in rap2 compared to raplA and raplB [l]. 
To investigate the distribution of small GTP-binding pro- 
teins in different mammalian cell lines, membranes were first 
probed with 142-24E05 mAb, which is strongly reactive 
against ras and rapl proteins (Fig. 2). This antibody detected 
proteins in the 22 - 23-kDa range in all cells tested, although 
at different levels (Fig. 3). Whereas in membranes from human 
thrombocytes and 3T3-Swiss Albino fibroblasts immuno- 
reactivity was high, intermediate levels were seen in mem- 
branes from the leukemic cell lines HL-60, P388D1, K-562 and 
HEL, and little immunoreactivity was detected in membranes 
from lymphoma cell lines U-937 and S49.1 cyc-. HL-60, U- 
937, K-562, and HEL cell lines are of human origin, whereas 
P388D1, S49.1 cyc- and 3T3-Swiss Albino cell lines are of 
mouse origin. To characterize the subtypes of rap proteins 
present in the membranes, we next reacted affinity-purified 
antibodies against subtypes of rap proteins. Rapl A-antiserum 
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Fig. 4. Immunoblot analysis of rap and ras proteins in membrane and 
cytosolic fractions from HL-60 cells treated with lovastatin. HL-60 cells 
were treated for 72 h with 10 pM lovastatin or its vehicle (control). 
SO pg of membrane proteins from control (lane 1) and lovastatin- 
treated HL-60 cells (lane 2) and 50 pg cytosol proteins from control 
(lane 3) and lovastatin-treated HL-60 cells (lane 4) were subjected to 
SDSjPAGE and transferred to nitrocellulose. Blots were reacted with 
142-24E05 mAb (A), affinity-purified rapl A-antiserum 213 (B), 
rap1B-antiserum 218 (C), rasll mAb (D). Values on the right indicate 
the position of molecular-mass-marker proteins. 
teins in membranes from HEL and P388D1 leukemic cells, 
intermediate levels in membranes from HL-60 and K-562 
leukemia cells and low levels in membranes from U-937 and 
S49.1 cyc- lymphoma cells as well as in membranes from 
human thrombocytes and 3T3-Swiss Albino fibroblasts 
(Fig. 3). In contrast, with raplB-antiserum 218 high levels of 
immunoreactive 22 -23 kDa proteins were demonstrated in 
membranes from human thrombocytes, 3T3-Swiss Albino fi- 
broblasts and HEL cells (Fig. 3). Intermediate levels of raplB 
were found in membranes from HL-60, P388D1 and K-562 
leukemia cells, whereas, as in the case of raplA, raplB 
immunoreactivity was barely detectable in membranes from 
U-937 and S49.1 cyc- lymphoma cells (Fig. 3). Interestingly, 
affinity-purified rap2-antiserum 221, which has been shown 
to display strong immunoreactivity against recombinant rap2 
protein (Fig. 2), detected only minor immunoreactive bands 
in the 20 - 24 kDa range in membranes of some cells tested 
(Fig. 3). We used rasll  mAb to analyze the levels of ras pro- 
teins in membranes from mammalian cell lines and human 
thrombocytes. As shown in Fig. 3, ras immunoreactivity in 
the 21 -22 kDa range was clearly detectable in membranes 
from HL-60, P388D1, K-562, 3T3-Swiss Albino cells and hu- 
man thrombocytes, whereas ras proteins were present at lower 
levels or were barely detectable in membranes from HEL, 
U-937 and S49.1 cyc- cells. 
It has been demonstrated for ras proteins that isoprenyla- 
tion of the C-terminus is a prerequisite for proper membrane 
insertion. To test whether raplA and raplB proteins are 
isoprenylated in membranes from HL-60 cells, we treated HL- 
60 cells with lovastatin, an inhibitor of hydroxymethyl- 
glutaryl-coenzyme A reductase, and thereby, of isoprenyla- 
tion. Membranes and cytosol from control and lovastatin- 
treated HL-60 cells were subjected to immunoblot analysis 
with several antibodies. Application of 142-24EO5 mAb, 
which is highly reactive against ras and rapl proteins (Fig. 2), 
showed that levels of immunoreactive proteins were decreased 
in membranes from lovastatin-treated HL-60 cells, whereas 
immunoreactivity in the cytosol was strongly increased 
(Fig. 4). Specific antibodies against raplA, raplB and ras 
proteins (Fig. 4) showed that treatment of HL-60 cells with 
lovastatin affected the membrane concentration of small 
Fig. 5. Estimation of raplA and ras protein levels in membranes from 
HL-60 cells by immunoblot analysis. (A) SO pg membrane proteins 
from HL-60 cells (lane 1) and 30 ng (lane 2), 10 ng (lane 3), 3 ng 
(lane 4) of recombinant raplA protein were subjected to SDSIPAGE, 
transferred to nitrocellulose and reacted with affinity-purified rapl A- 
AS 213. (B) 50 pg of membrane proteins from HL-60 cells (lane 1) 
and 30 ng (lane 2), 10 ng (lane 3) and 3 ng (lane 4) of recombinant 
c-Ha-ras protein were subjected lo SDS/PAGE, transferred to nitro- 
cellulose and reacted with rasl l  mAb. Values on the right indicate the 
position of molecular-mass-marker proteins. 
GTP-binding proteins in a different way. After lovastatin 
treatment, the membrane content of raplA and raplB protein 
was reduced to about 20% or 60% of the control respectively, 
whereas the ras level did not change significantly. Analysis of 
cytosol from untreated HL-60 cells demonstrated the presence 
of low levels of both raplA and raplB immunoreactivity and 
intermediate levels of ras immunoreactivity. Whereas concen- 
trations of unprocessed raplA and rapl B proteins increased 
very strongly in the cytosol of lovastatin-treated HL-60 cells, 
concentrations of immature ras proteins increased only mod- 
erately. The differential effect of lovastatin on membrane 
levels of ras, raplA and rapZB proteins is most likely due to 
different half-lives of these proteins in HL-60 cells. RaplA 
and raplB proteins in the cytosol of lovastatin-treated HL-60 
cells consist of two immunoreactive bands, the upper one, 
with slightly decreased electrophoretic mobility, suggesting an 
unprocessed form of these proteins. 
Differentiation of HL-60 cells towards neutrophils with 
dibuturyl CAMP (0.2 mM) for 48 h did not lead to significant 
changes in the levels of raplA and raplB proteins in mem- 
branes or cytosol (data not shown). 
We used our specific antibody against raplA to measure 
the amount of raplA protein in membranes from HL-60 cells 
(Fig. 5). Comparison with recombinant raplA protein [I 51 is 
hampered by the fact that the purified protein consists of 
two well-separated immunoreactive bands. By evaluating the 
intensity of raplA (ras) immunoreactivity in membranes and 
purified recombinant rapl A (c-Ha-ras), we calculated that 
raplA constitutes about 0.04% of membrane proteins, 
whereas ras proteins constitute about 0.01% of membrane 
proteins. 
DISCUSSION 
We have generated specific antibodies against the small 
GTP-binding proteins rapl A, raplB and rap2. Although the 
production of antibodies against rap1 proteins has been de- 
scribed by several groups [24, 25, 361, no subtype-specific 
21 1 
antibodies against raplA or raplB have been described so far. 
RaplA and raplB proteins share 95% amino acid similarity, 
but the C-terminal sequences are less conserved. This in line 
with the observation that C-terminal amino acid sequences of 
ras proteins show only little similarity between Ha-ras, Ki-ras 
and N-ras. To generate specific antibodies against raplA and 
raplB, we synthesized peptides comprising the 14 amino acids 
from the extreme C-terminus of processed raplA and raplB 
proteins. These antibodies specifically recognized the corre- 
sponding recombinant proteins and, furthermore, reacted 
with proteins of 22-23 kDa molecular mass in membranes 
from various mammalian cell lines and human thrombocytes. 
To generate rap2-specific antibodies, we synthesized a 
peptide comprising amino acids 164- 177 of the rap2 protein. 
Although the rap2 antibody was strongly reactive against 
recombinant rap2 protein, we found no clear immunoreactive 
bands in the 20 - 24 kDa region using membranes from sev- 
eral mammalian cell lines and human thrombocytes. We can- 
not exclude the possibility that rap2 levels in membranes from 
cells tested were beyond the sensitivity of our immunoblot 
analysis. Alternatively, yet unknown posttranslational modifi- 
cations may inhibit recognition of rap2 in membranes from 
mammalian cells, whereas the antiserum is highly reactive 
against recombinant rap2. 
An interesting picture emerges from our analysis of raplA 
and rapl B immunoreactivity in membranes prepared from 
various leukemia and lymphoma cell lines. Whereas raplA 
and raplB proteins were present in substantial amounts in 
membranes from human leukemia cell lines HL-60, K-562, 
HEL and mouse leukemia cell line P388D1, both proteins 
were barely detectable in membranes from human histiocytic 
lymphoma cell line U-937 and mouse lymphoma cell line S49.1 
cyc-. In most of these cell lines, raplA immunoreactivity is 
higher compared to raplB immunoreactivity. The situation is 
different for membranes prepared from human thrombocytes 
and mouse 3T3-Swiss Albino fibroblasts, where raplB is pre- 
sent at much higher levels compared to raplA. 
By subcellular fractionation and reaction with an anti- 
serum recognizing both raplA and rapl B proteins, rapl 
immunoreactivity was localized exclusively in the particulate 
fraction of Rat-1 fibroblasts and HL-60 cells [25]. In contrast 
to these data, we find low but detectable raplA and raplB 
immunoreactivity in the cytosol of HL-60 cells, as was also 
demonstrated for the cytosol of human platelets [36]. 
Culine et al. [37] studied the expression of rap genes in 
various human tumors and cell lines by Northern-blot analy- 
sis. raplA and raplB mRNA are apparently expressed at 
similar levels in the various cells examined in this study. This 
fits our data showing that raplA and raplB immunoreactivity 
in membranes of several cell lines is comparable. Additionally, 
expression of rap2 mRNA is low in all cells examined [37]. 
Our failure to detect rap2 immunoreactivity in membranes 
from tested mammalian cell lines and human thrombocytes 
may be explained by the presence of low levels of rap2 mRNA, 
and thereby rap2 protein, in these cells. 
With both raplA and raplB antibodies we find multiple 
immunoreactive bands in the 22 - 23 kDa range in membranes 
from all cells tested including HL-60 cells. This heterogeneity 
appears not to rely on proteolysis during membrane prep- 
aration, since the addition of various commonly used protease 
inhibitors did not reduce the number of immunoreactive bands 
in membranes prepared from HL-60 cells (data not shown). 
Winegar et al. [36] recently reported that a rapl-common 
antiserum detects immunoreactive bands of 22 kDa and 
24 kDa in membranes from human platelets. In this study, an 
antiserum recognizing the unprocessed form of rapl B protein 
reacts exclusively with a 24-kDa band [36]. Our data using 
antibodies specific for raplA or raplB proteins, but not selec- 
tive for the unprocessed or processed forms of these proteins, 
demonstrate that raplA is only present in low amounts in 
platelet membranes. The upper 23 kDa band stained by our 
raplB antibody may consist of unprocessed raplB. It should 
be noted, however, that the 23 kDa bands recognized by 
raplA or rdplB antibodies are not restricted to differentiated 
cells like human thrombocytes, but can also be seen in mem- 
branes from various mammalian cell lines. In addition to C- 
terminal processing, heterogeneity of rapl proteins could also 
rely on other posttranslational modifications such as phos- 
phorylation. Indeed, it has been shown, that the rapl proteins 
are phosphorylated by CAMP-dependent protein kinase and 
that the electrophoretic mobility of the protein is altered by 
phosphorylation [38, 391. 
Like ras proteins [lo], rap proteins are expected to undergo 
a complex processing of C-terminal sequences. To examine 
whether raplA and raplB were isoprenylated in membranes 
from HL-60 cells, HL-60 cells were treated with lovastatin, 
an inhibitor of hydroxymethylglutaryl-coenzyme A reductase 
and thereby of isoprenoid biosynthesis. Whereas rapl A and 
rapl B immunoreactivity was reduced in membranes from cells 
treated with lovastatin, we observed a strong accumulation of 
immunoreactivity in the cytosol. Ras immunoreactivity in 
membranes did not change significantly after treatment of 
HL-60 cells with lovastatin. The fact that ras immuno- 
reactivity was slightly increased in the cytosol of lovastatin- 
treated HL-60 cells is in line with results showing that ras 
proteins are isoprenylated in mammalian cells. The different 
action of lovastatin on ras and rapl proteins suggests that the 
half-life for ras proteins in membranes from HL-60 cells is 
much longer than that for rapl proteins. As a consequence 
of different half-lives for isoprenylated proteins, drugs like 
lovastatin, which unspecifically block the isoprenylation of 
these proteins, may selectively decrease membrane levels of 
defined small GTP-binding proteins in short-term exper- 
iments. Treatment of HL-60 cells with 10 pM lovastatin for 
72 h did not affect cell growth (data not shown), a result that 
is in line with unchanged levels of ras proteins in membranes 
from lovastatin-treated HL-60 cells. 
Overexpression of raplA (Krev-1) cDNA in ras-trans- 
formed fibroblasts leads to suppression of the transformed 
phenotype, but membrane levels of ras and raplA proteins 
were not measured in this study [6]. In comparison with 
purified recombinant rdplA and c-Ha-ras protein, we esti- 
mated the ratio of raplA/ras in membranes from HL-60 cells 
and found the raplA protein to be present in about fourfold 
greater amounts than ras proteins. It has been shown that 
HL-60 cells possess an activated N-ras oncogene together with 
altered versions of the myc oncogene [40]. If the activated N- 
ras oncogene were linked to oncogenic transformation in these 
cells, one would expect that overexpression of the raplA pro- 
tein inhibits the transformed phenotype, as has been described 
for fibroblasts [6]. Corresponding to our data, a moderate 
excess (about fourfold) of the potential tumor suppressor pro- 
tein raplA above ras is apparently not sufficient to keep HL- 
60 cells in an untransfomed state. 
In conclusion, we have generated specific antibodies 
against the raplA, raplB and rap2 small GTP-binding pro- 
teins. By immunoblot analysis, we have shown that concen- 
trations of raplA and raplB are highly variable in membranes 
from different mammalian cell types and that both proteins 
are isoprenylated. 
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